+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07285655

Evaluating Safety and Effects of L606 Inhalation for Pulmonary Hypertension Associated with Interstitial Lung Disease in a Randomized, Placebo-Controlled Study

Led by Liquidia Technologies, Inc. · Updated on 2026-10-14

344

Participants Needed

44

Research Sites

126 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of L606 in people with pulmonary hypertension caused by interstitial lung disease PH-ILD, WHO Group 3. The study focuses on whether L606 helps participants walk further in six minutes, using the six-minute walk test as a main measure. It also examines how long it takes for PH-ILD to worsen under treatment, alongside close monitoring for any side effects. Participants are randomly assigned to receive either L606, a liposomal form of treprostinil delivered by inhalation with a nebulizer, or a placebo that looks like L606 but contains no active medicine. After the initial blinded phase, participants may join an open-label extension where all receive L606. The study uses a parallel design with quadruple masking to compare outcomes between groups. During the trial, participants will attend visits to assess walking distance at multiple time points, monitor lung health, and watch for side effects. Key measurements include changes in six-minute walk distance at 16 and 24 weeks and the time until worsening events like hospitalization or lung transplant. The study is expected to continue until 2031, with safety and efficacy carefully tracked throughout.

CONDITIONS

Brief Title

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Research Team

L

Liquidia Point of Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here